The mission of the Oregon State Board of Pharmacy is to promote, preserve and protect the public health, safety and welfare by ensuring high standards in the practice of pharmacy and by regulating the quality, manufacture, sale and distribution of drugs.

WEDNESDAY, FEBRUARY 8, 2017

Kate James, R.Ph, Board President, called the meeting to order at 8:34AM.

Roll Call
Kate James, President                     Penny Reher, Vice President
Roberto Linares                           Ken Wells
Christine Chute                           Heather Anderson
Rachael DeBarmore                         Cyndi Vipperman
Dianne Armstrong

The following staff members will be present for all or part of this session:
Marc Watt, Executive Director            Brianne Efremoff, Compliance Director
Karen MacLean, Administrative Director   Chrisy Hennigan, Licensing Program Supervisor
Joe Ball, Chief Investigator             Fiona Karbowicz, Pharmacist Consultant
Cheryl Fox, Inspector                    Katie Baldwin, Inspector
Laura Elvers, Inspector                  Annette Gearhart, Compliance Secretary
Kim Oster, Compliance Assistant          Mo Klein, Project Manager
Rene Sanders, Licensing Representative

Tom Cowan, Sr. AAG Board Counsel

Agenda Review and Approval

MOTION
Motion to approve the Agenda was made and unanimously carried (Motion by Anderson, seconded by Wells).

Contested Case Deliberation pursuant to ORS 192.690(1) - Not Open to the Public

EXECUTIVE SESSION – NOT OPEN TO THE PUBLIC, pursuant to ORS 676.175, ORS 192.660 (1) (2) (f) (k).

A. Items for Consideration and Discussion:
   1. Deliberation on Disciplinary Cases and Investigations
   2. Personal Appearances
   3. Warning Notices
4. Case Review

MOTION
Motion to enter Executive Session at 8:37AM was made and unanimously carried (Motion by Chute, seconded by Armstrong).

MOTION
Motion to enter Open Session at 1:24PM was made and unanimously carried (Motion by Anderson, seconded by Armstrong).

Employee Performance Review pursuant to ORS 192.660(2)(i).

MOTION
Motion to enter Executive Session pursuant to ORS 192.660(2)(i) at 1:33PM was made and unanimously carried (Motion by Wells, seconded by Armstrong).

MOTION
Motion to resume Open Session at 1:55PM was made and unanimously carried (Motion by DeBarmore, seconded by Chute).

OPEN SESSION - PUBLIC MAY ATTEND - At the conclusion of Executive Session, the Board may convene Open Session to begin the scheduled agenda for February 8, 2017.

Approve Consent Agenda*

*Items listed under the consent agenda are considered routine agency matters and will be approved by a single motion of the Board without separate discussion. If separate discussion is desired, that item will be removed from the consent agenda and placed on the regular business agenda.

1. NAPLEX Scores – none
2. MPJE Scores – none
3. License/Registration Ratification - December 7, 2016 – February 6, 2017
4. Extension Requests - none

MOTION
Motion to approve Consent Agenda was made and unanimously carried (Motion by Wells, seconded by DeBarmore).

Adjourn

MOTION
Motion to adjourn at 1:56PM was made and unanimously carried (Motion by DeBarmore, second by Chute).
THURSDAY, FEBRUARY 9, 2017

Kate James, R.Ph, Board President, called the meeting to order at 8:32AM.

Roll Call
Kate James, President    Penny Reher, Vice President
Ken Wells              Christine Chute
Heather Anderson      Rachael DeBarmore
Cyndi Vipperman      Dianne Armstrong

Roberto Linares – excused absence

The following staff members will be present for all or part of this session:
Marc Watt, Executive Director   Brianne Efremoff, Compliance Director
Karen MacLean, Administrative Director   Chrisy Hennigan, Licensing Program Supervisor
Joe Ball, Chief Investigator   Fiona Karbowicz, Pharmacist Consultant
Cheryl Fox, Inspector   Katie Baldwin, Inspector
Laura Elvers, Inspector   Annette Gearhart, Compliance Secretary
Kim Oster, Compliance Assistant   Mo Klein, Project Manager
Rachel Melvin, Executive Support Specialist   Rene Sanders, Licensing Representative
Tim Ma, Board of Pharmacy Intern

Tom Cowan, Sr. AAG Board Counsel

Motions for Contested Cases & Disciplinary Action – Please see Motions for Disciplinary Cases at the end of this document.

GENERAL ADMINISTRATION

Rules
Review Rulemaking Hearing Report & Comments – None
Consider Adoption of Temporary Rules - None
Consider Rules and send Rulemaking Hearing - None
Consider Adoption of Rules - None

Policy Issues for Discussion

Executive Director, Marc Watt mentioned that he had received a number of calls regarding possible abuse of a drug called Kratom (Mitragyna) and he asked for the Boards input. This drug was presented to the Board last year for consideration. It is available for purchase online, head shops, gas stations, etc. Marc reached out to the Oregon State Police (OSP) and last year they reported that they see one case per year related to this drug, but they have seen three cases in the last month, two of those contributed to overdose deaths. 2017 SB 518 currently directs the Board to conduct a study and report back to the legislature after a two-years to see if it contributes to DUII, overdose, positive results in UAs, etc. Marc pointed out that the Board has the existing authority to evaluate potential scheduled drugs and asked the Board about looking into this, as it seems to be an emerging problem locally and at a national level. Marc asked if we should proactively research this drug more and create language to bring the Board. Board
Member, Penny Reher asked Board Member, Christine Chute if the Governor’s DUII Advisory Committee had addressed this drug. Christine stated that the committee has heard of it, and will ask the Chiefs of Police at their next meeting if they are seeing this as more of a problem. Marc stated that it’s becoming an issue on the east coast and that Khat is another drug that is similar and should be looked at. Penny stated that with Oregon’s current opioid abuse issue, it warrants a closer look as opioids become less available. Board Member, Ken Wells wants to know if other states are taking action and Marc stated that the DEA was moving towards making this a Schedule 1 drug. The Board decided to wait until the current Legislative session concluded before moving forward.

Wholesaler Reporting Requirement

Executive Director, Marc Watt discussed a press release from the DEA about McKesson Corporation agreeing to pay a record $150 million civil penalty for alleged violations of the Controlled Substance Act (CSA). Marc stated that other Boards have had warning signs and suggested that we take a hard look at this and draft a rule. Board Member, Dianne Armstrong asked if the DEA is the agency that caught McKesson. Board Member, Ken Wells stated that he was astonished by the report and thinks it would be beneficial for patient safety. Board President, Kate James stated that she was surprised that we do not have rules on reporting requirements on this topic already. Board Member, Heather Anderson asked what the agency does when we receive a report like this. Marc explained that our Compliance team would investigate and evaluate by looking at the history on a case-by-case basis. The Board agreed that this is something they want to pursue and Pharmacist Consultant, Fiona Karbowicz stated that a partnership with DEA would be useful.

Pharmacy Depot

Pharmacist Consultant, Fiona Karbowicz provided an overview of the rule and the historical intent for use of Pharmacy Depot. She stated that it was crafted as an allowance for delivery for patients with special circumstances, which allowed for example, refrigerated drugs to be delivered to a non-pharmacy location, like their home or workplace; typically, this might be used in rural areas. More recently, the Board was asked to create a place, not a pharmacy, not direct to home, like mail order.

The purpose of this discussion was to ask the Board if they want to stay with the traditional interpretation of how depot was intended to be used or do they want to create a mechanism for technology or other types of delivery systems.

The Board is concerned about losing the pharmacist to patient relationship and the opportunity to counsel upon dispensing. Executive Director, Marc Watt stated that some concepts that address this might be remote dispensing machines vs. depot rule. Board Member, Christine Chute asked if this was regarding abuse of the current drug depot rule. Fiona stated that she didn’t know if the depot rule is being perceived this way and that our rule is simply a rule, it’s not a license type and that we don’t know where this occurring on a larger scale. Marc stated it is a pre-emptive discussion and its complex and Christine stated she prefers to address this in a pro-active way as specific problems arise. Board Member, Heather Anderson stated that we should ask outlets if they are utilizing the Depot rule. Board Vice President, Penny Reher stated in her organization, they have staff (IT and Admin.) that work at off-site locations and they asked about putting staff
drugs in a locked room. They were told no, that’s not allowed, OBOP staff indicated that a patient’s workplace doesn’t mean delivery to their desk or to another person. Board Member, Rachael DeBarmore asked if pharmacies are able to drop off at residential living communities like a retirement center as their primary residence.

Marc supported the primary residence concept. He gave an example of when there was a mis-delivery of a very expensive medication to a place of business, the drug was not refrigerated and the pharmacy was responsible for the loss, which prompted that retail pharmacy to ask the Board for clarification of the rule. Board Member, Ken Wells stated the intent of the rule was to address isolated incidents more of a one-on-one. He liked the idea of addressing this, just not in the Depot rule and that patient safety is the main concern. He wants assurance that a pharmacist is available for counseling, especially on the first dispensing; that they have access to the drug utilization review, that the delivery environment is safe, secure and controlled.

Marc mentioned that he saw some examples of dispensing machines at the NACDS meeting last year. He was able to see how the technology worked and indicated that it addressed the security, the consult, etc. Penny participated on a NABP Telepharmacy Taskforce and mentioned that every state is writing rules on what to allow technology and that North Dakota has a good rule in place for their rural patients that have little or no access. She said some states have best practices and have been keeping up with the available technology, and have a roadmap we could use. She thinks there are ways we can do this safely and proactively. Marc did confirm though that they do have access to a pharmacist and Penny confirmed yes.

Board Member, Dianne Armstrong asked about if care facilities are utilizing the depot rule and Marc explained that in long-term care, prescriptions are delivered to a healthcare provider, not the building. Marc asked the Board if we need to keep track of inquiries and how we engage the conversation. The Board agreed that they would like to review this issue. Marc also expressed concern about how controlled substances are being handled in Depot situations. Christine said this rule was an exception, not a way to do business. Penny stated that when she was first on the Board that her employer removed this technology from hospitals because the doctors would not use it, so patients left hospital without the medication they needed. Board Counsel, Tom Cowan stated in terms of drafting the rule, that it would be good to articulate the preference and define the nature of patient and pharmacist relationship.

Rules in the Pipeline

Pharmacist Consultant, Fiona Karbowicz had no new rules to discuss, but presented a brief update of rules for discussion later this year. Fiona shared that the updated language for Auto Refill will be presented at the next meeting for a possible rulemaking hearing in May, and the DPDO rulemaking hearing is happening on March 7. The Division 045 Compounding rule draft is scheduled for first review at the August 2017 meeting as well as anything additional that legislative session produces. Fiona stated that the Remote Distribution Facilities rule is not being utilized properly and the language is not clear. We are continuing to receive ambulatory infusion questions, which are about administration not distribution, and this is not just an Oregon issue. We will need to edit Division 035 Medical Devices rule, because it needs more clarity. Fiona described the concept of mandatory counseling and gave an example using the Naloxone rule, which states that the pharmacist cannot refuse counseling, because it’s in the rule. Administrative Director, Karen MacLean stated that five-year rule reviews are coming up and that she will submit the January approved rules to the Secretary of State’s office soon. Executive Director, Marc Watt shared some rule statistics from 2016 and stated that 59 rules were adopted, amended or
Board Member, Christine Chute wanted to know how the licensees are coping with all of these changes and asked if we can group changes together to be more deliberate. Marc stated that we set aside time in our agenda twice per year, to achieve the revisions, approvals, etc., but the state introduces multiple bills that are generated from legislative session that require us to create or revise rules. Marc advised that we are slowing down the rulemaking development down this year due to the legislative session and key staffing changes.

Discussion Items

Waiver Requests – none

OHSU TCVP One year report

Compliance Director, Brianne Efremoff and Pharmacist Consultant, Fiona Karbowicz asked the Board if they had any questions regarding OHSU’s Technician Checking Validation Program (TCVP) one-year report and stated that the Board needs to give an official response to one question. The Board reviewed OHSU’s questions: Does the current Board approval include all OHSU Operating Rooms? Can ambulatory pharmacy use TCVP? Does the OHSU approved process allow TCVP to be utilized for their Center for Health and Healing operating room non-emergent trays? Does a new proposal need to be approved for a different location? The Board’s recommendations were as follows: The Board issues each individual license, specific to functionality and facility address. The Board does not approve “campus” registrations. The 2013 approval was given for the main inpatient hospital’s TCVP program only (located at 3181 SW Sam Jackson Rd.) The TCVP rules (OAR 855-041-5100 – 5170 are specific to hospital outlets (see OAR 855-041-5120(1)). The CHH Ambulatory Infusion location is not eligible for TCVP, as the rules are currently written. TCVP requests are location specific. Any new location would require a new request. Yes, it is acceptable to have two program coordinators. It would be beneficial to have one in each location to oversee their respective site, and it is recommended that each location within system is following the same P&P for consistency. Board Vice President, Penny Reher stated that she believes it is appropriate. Brianne stated that staff would follow up with OSHU with the official response.

MOTION

Motion to accept OHSU’s TCVP one year implementation report and report back in October 2018 to renew was made and unanimously carried. (Motion by Anderson, seconded by Wells).

Opioid PDMP Trend

Executive Director, Marc Watt shared statistics from the OHA Prescription Drug Monitoring Program (PDMP) that showed the rate of statewide prescriptions for the top two opioids has decreased dramatically from prior the prior year 4th Quarter statistics. The top two prescriptions, Hydrocodone -15.3% and Oxycodone -11.2% were both on a downward path, but Marc stated that he wasn’t sure what contributed to the decline and mentioned the DEA is restricting production in 2017.
Recognition of outgoing Board Member Heather Anderson

Board President, Kate James highlighted Heather’s contributions to the Board, some key areas included: her participation on the original rule development for Auto-Refill and ongoing workgroup activities; attending almost rulemaking hearing during her term; a strong advocate for outlet and individual accountability and patient safety, no excuses! Heather also arranged for an appearance for the Board related to Certain Aspects of Licensing Anti-Trust and Anti-Consumer issues. Board Member, Ken Wells expressed his gratitude for both public Board Members, and stated that it makes professional Board Members better at what they do, and then he thanked Heather. Executive Director, Marc Watt thanked Heather for her perspective and her time. Board Member, Christine Chute, said she really appreciated Heather’s perspective and wished her all the best. Vice President, Penny Reher, called Heather brilliant, amazing, one of a kind and that it was a pleasure to get to know her and that she appreciated Heather’s unique perspective and thanked her for her time. Board Member, Dianne Armstrong stated that Heather was a pistol and thanked her for her time. Kate wished Heather the best and presented her with a plaque and t-shirt. Heather thanked everyone for a very interesting chapter in her life story and shared that she ended up serving on our Board because she was looking for a place to give back. Her takeaways are that Pharmacists are loyal and we have quality people on the Board and in this industry. Her last statement was “what we do is important and never minimize it”.

ISSUES/ACTIVITIES

Reports:

Board President/Members – None

Executive Director Marc Watt stated that the snowstorm situation in Portland really affected our agency the last few months. He has been working on HPSP transfer and that Administrative Director Karen MacLean will attend the next HPSP meeting. Marc mentioned that DOJ has turned up their focus on Medicaid/Medicare fraud and that he was able to sit down with them and strengthen that relationship to share information. Marc has been working closely with Compliance Director Brianne Efremoff during her transition and is looking to dial back his participation going forward. The drug-take back bill, which charged us with a statewide take back with manufacturers, in which we have no experience negotiating that kind of contract, was too complex. A partnership with the DEQ that will allow us to re-write the bill where DEQ would negotiate with manufactures, where the drugs go and how they are disposed and then our agency would oversee the drop-off at boxes. An amendment should go in soon and Marc finished his report stating that we had hired two Inspectors, Jane Gin and Brian Murch who are starting soon.

Marc also reported the we recently learned that PTCB’s 2020 training and exam criteria has been withdrawn, they are going back to stakeholders to rethink their plan and he thinks we need to move forward with what we discussed at Strategic Planning.

Board Counsel – Tom congratulated the Board on the smooth transition promoting Brianne Efremoff to Compliance Director and replacing Gary Miner, said it’s been seamless. Stated that we had a robust contested case and was very pleased with Executive Directors performance as well as staff on the investigation.
Compliance Director- Brianne Efremoff stated that she was inundated with trying to fill large shoes, thanked everyone for helping her during the transition.

Pharmacist Consultant – Fiona Karbowicz highlighted the PIC outreach live-streaming event with OSU and said it was a first of its kind and that it went well and she thanked Pharmacy Inspector, Katie Baldwin and Compliance Director, Brianne Efremoff. She estimated that 25 Retail and 10 to 15 Hospitals logged in to participate in the webinar. She mentioned that since Gary Miner’s departure, she has taken over CE and Shared Services Contract approvals and thanked staff for help with the transition. She mentioned that there are several CEs that are happening statewide daily. Shared Services requests are not just about compounding, which has brought up some questions and we possibly need to revise the template to drill down what the contract is being used for.

Administrative Director – Karen MacLean stated that she was busy preparing our budget presentation for the Ways and Means Committee and that there is a lot of training happening with our new Project Manager, Mo Klein. She stated that she had attended a DAS meeting of small boards and commissions that was very interesting and that the 17-19 Affirmative Action policy was approved by the Governor's office and has been added to our website and sent to all staff and board members for review. Karen attended the latest HPSP Work Group meeting and continues to work on contract transition administration issues. She also been busy working on all of our rules.

Licensing Program Supervisor- Chrisy Hennigan stated that our pharmacy renewal online system has been incredible and is saving the staff a lot of time. Licensing staff is currently working on catching up on PIC changes and updating our PIC online form, which will auto-generate a confirmation email to the licensee confirming we received it. Chrisy participated in a conference call regarding eligibility requirements and she is working with Pharmacist Consultant, Fiona Karbowicz on sending out reminder notices to pharmacists regarding CE requirements in preparation for the upcoming biennial renewal, as well as a reminder notice to Technicians with licenses that expire in June. Chrisy completed second round interviews for the open Licensing Representative position and expects to make an offer within a week. Fiona thanked Licensing and Compliance staff for their help with the license conversion from Family Planning to Community Health Clinics. Even though she did outreach and FAQ's, she stated that it has been quite a manual process.

Project Manager- Mo Klein didn’t have anything to report but Executive Director, Marc Watt stated that we are utilizing Mo’s skillset to help us evolve some of our internal processes.

---

**Board Member/Staff Presentations**

Pharmacy Coalition – Pharmacist Consultant, Fiona Karbowicz attended the meeting on February 7 and said it was a great meeting and Session is an exciting time. The Coalition members talked about their focus on a couple of specific goals.

Professional Practice Roundtable - Pharmacist Consultant, Fiona Karbowicz attended the meeting on January 17. This group has been around since 2006, and continues to be a useful forum for discussion.

Health System Outreach Meeting Pharmacist Consultant, Fiona Karbowicz attended this meeting on February 7, and stated that it was similar to Professional Practice Roundtable, but is for
hospitals as a place to share best practices, ideas, etc., Board expectations. They plan on meeting quarterly.

Health Futures – Compliance Director, Brianne Efremoff and Pharmacist Consultant, Fiona Karbowicz will attend this meeting on February 17 in Eugene where they’ll give a one-hour presentation with a focus of controlled substance accountability.

Douglas Co. Pain Summit – Pharmacist Consultant, Fiona Karbowicz will present at this meeting with a focus on Naloxone & Drug Take Back in Roseburg on March 21. It will be a twenty-five minute presentation for attendees from all over southern Oregon. The DEA’s 2017 APQ (Aggregate Production Quota) reduction, limiting opiates being manufactured will be discussed as well.

Pharmacist Consultant, Fiona Karbowicz will present at the So. OR CCOs to Pharmacists in Grants Pass and Medford on March 21 & 22 and will present to Pharmacists in Coos Bay and Brookings on April 11 & 12. This presentation will consist of the “nuts and bolts” of the rule for pharmacists prescribing Naloxone & Drug Take Back. She will discuss the rules and answer questions we have been receiving, as well as best practices for pharmacists.

Committees/Meetings

OSPA Lane Co. Mid-Winter Meeting will be held February 18-19 in Eugene, and Board Member Ken Wells, Compliance Director Brianne Efremoff and Pharmacy Inspector Cheryl Fox. Ken, Brianne and Cheryl created a presentation that covered items such as rule changes, drug storage, and Naloxone. Ken has attended in the past and mentioned that attendance has been great in the past and that Board President, Kate James is co-chair. Good opportunity for southern OR pharmacists to attend.

NABP Annual Mtg. 5/20-23/2017, Orlando, FL – Board Vice President, Penny Reher will be the voting delegate from Oregon. Penny mentioned that on February 11, Linn-Benton County had a one-hour presentation from OSU regarding how marijuana has been impacting patients.

APhA Institute on Alcoholism and Drug Dependencies 6/1-4/2017, Salt Lake City, UT – New Inspector, Brian Murch will be attending this meeting as a training opportunity for investigations. A travel grant is available and we will be applying for one to cover expenses.

Board Meeting Dates

- April 5-6, 2017 Portland
- June 7-8, 2017 Portland
- August 9-11, 2017* Portland (*3 day meeting)
- October 11-12, 2017 Portland
- November 8-9, 2017 TBA (Strategic Planning)
- December 13-14, 2017 Portland
- February 7-9, 2018* Portland (*3 day meeting)
- April 4-5, 2018 Portland
- June 6-7, 2018 Portland
- August 8-10, 2018* Portland (*3 day meeting)
- October 3-4, 2018 Portland

Minutes – February 8-9, 2017
Page 9 of 11
Financial/Budget Report

Executive Director, Marc Watt presented the agency budget to the Ways & Means Committee on February 7, and stated that it was enlightening to present the tremendous work that we do at OBOP. Some of the highlights were the makeup of our Board and the impact they have made, receiving more and more requests for outreach and the large amount of applications and licenses we processed. Board President, Kate James stated that she attended the hearing as an audience member and said Marc did very well and thanked him for his service.

Legislative Update

Executive Director, Marc Watt spoke about the priority #1 Bills that we are tracking such as:
- HB 2128 related to deleting pseudoephedrine as a Schedule III drug. A rule revision would be necessary.
- HB 2386 directs manufacturers that sell certain drugs in Oregon to develop and implement a drug takeback program. Rules will need to be developed.
- HB 2394 allows participating health boards to refer licensees to HPSP for monitoring who have been convicted of certain alcohol or drug related crimes.
- HB 2395 relates to adopting rules about prescription labels, Fiona provided information at the February 6 hearing.
- HB 2397 is an effort to create an entity to create boundaries to allow pharmacy related statewide protocols. This is being championed by the Pharmacy Coalition.
- HB 2527 adds two new categories that were left out of original contraception bill. This will allow pharmacists to prescribe and dispense self-administered hormonal contraceptives such as NuvaRing and Depo-Provera, but would not allow Norplant.
- HP 2114 prohibits issuing initial prescription for opioids or opiates to adults for outpatient use in quantity exceeding seven-day supply. Board Vice President, Penny Reher that she’s aware that some insurances are only paying for 7 days.
- HB 2517 relates to PDMP and sharing information with other states etc.
- HB 2518 relates to PDMP and requires pharmacy to report de-identified information upon dispensing prescribed Naloxone.
- SB 50 relates to increasing the number of health care professionals that need to complete pain management continuing education and increases CE to once every four years rather than the one time requirement that is currently in statute.

Administrative Director, Karen MacLean stated that there is a bill to require CE for suicide prevention that could be added eventually. Board Member, Heather Anderson asked if HB 2232
would impact us. It was mentioned that there is some confusion regarding the Affordable Care Act and some questions about it being repealed. The Governor’s office have modified some of their processes and procedures and have asked OBOP to provide a weekly report about board members and or staff that speak on behalf of themselves, as a citizen. Please report to Project Manager, Mo Klein if you are speaking or plan on speaking as a citizen. OBOP’s views are to be informative and neutral, we are not to take a position on any bills unless given express permission to do so.

Strategic Planning

Administrative Director, Karen MacLean stated she needed to review Donna Silverberg’s notes from the meeting and needed to finish the minutes for that meeting. She offered up the idea of having this year’s Strategic Planning meeting at the same venue as last year and the Board agreed that Oregon Gardens would work. She will have more information regarding the venue at the April meeting.

OPEN FORUM - At the completion of regular Board Business, any Board licensee or member of the public is invited to meet with the Board to discuss issues of interest.

Jacob Thompson from Providence wanted to add a few points to his last comments at our previous board meeting. He stated that Providence is all about engaging patients, being a part of CCO increases access, decreases costs. Providence has partnered with Asteris in 34 other states and believes that they will meet OBOP rules. He proposed that the Board approve a trial period for Asteris/Providence for technology prior to rule writing process.

Peter Addy from Yale University and Dept. of Veterans Affairs, a substance abuse therapist has done extensive research on Kratom. He stated that he has done a lot of research globally and stated in his opinion he did not think Kratom is a drug to be scheduled. Executive Director, Marc Watt asked for his contact information.

Adjourn

MOTION
Motion to adjourn at 11:26AM was made and unanimously carried (Motion by Anderson, seconded by DeBarmore).

Accepted by:

[Signature]

Marcus Watt, R.Ph.
Executive Director
Executive Session of the Board was held on Wednesday, Feb. 8, 2017 to discuss Compliance cases, followed by motions on Thursday, Feb. 9, 2017. Working lunch held on Feb. 8, 2017.

Board Members present for all or part of compliance session:
- Kate James, RPh, President
- Penny Reher, RPh, Vice President
- Heather Anderson, Public Member
- Christine Chute, Public Member
- Rachael DeBarmore, RPH
- Roberto Linares, RPH [present Wednesday only]
- Kenneth Wells, RPH
- Dianne Armstrong, CPT
- Cyndi Vipperman, CPT

Staff present for all or part of compliance session:
- Brianne Efremoff, RPH, Compliance Director
- Joe Ball, RPH, Chief Investigator
- Katie Baldwin, RPH, Board Inspector
- Laura Elvers, RPH, Board Inspector
- Cheryl Fox, RPH, Board Inspector
- Annette Gearhart, Compliance Secretary
- Kim Oster, Compliance Assistant
- Marcus Watt, R.Ph., Executive Director
- Karen MacLean, Administrative Director
- Fiona Karbowicz, R.Ph., Pharmacist Consultant
- Mo Klein, Project Manager
- Chrisy Hennigan, Licensing Program Supervisor
- Rene Sanders, Licensing Representative
- Thomas Cowan, Senior AAG

<table>
<thead>
<tr>
<th>Case Number</th>
<th>Motion Description</th>
<th>Motion by:</th>
<th>Seconded by:</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014-0317</td>
<td>Motion to accept Stipulated Final Order.</td>
<td>Christine Chute</td>
<td>Kenneth Wells</td>
<td>Motion unanimously carried.</td>
</tr>
<tr>
<td>2016-0077</td>
<td>Motion to accept signed Stipulated Consent Order.</td>
<td>Kenneth Wells</td>
<td>Heather Anderson</td>
<td>Motion unanimously carried.</td>
</tr>
<tr>
<td>2016-0143</td>
<td>Motion to accept Stipulated Consent Order.</td>
<td>Dianne Armstrong</td>
<td>Kenneth Wells</td>
<td>Motion unanimously carried.</td>
</tr>
<tr>
<td>2015-0442</td>
<td>Motion to accept Stipulated Consent Order.</td>
<td>Kenneth Wells</td>
<td>Heather Anderson</td>
<td>Motion unanimously carried.</td>
</tr>
<tr>
<td>2014-0151</td>
<td>Motion to remove no PIC sanction of probation with completion of Board Pharmacist-in-Charge class.</td>
<td>Christine Chute</td>
<td>Heather Anderson</td>
<td>Motion unanimously carried.</td>
</tr>
<tr>
<td>2013-0509</td>
<td>Motion to remove no PIC sanction of probation and allow him to float between two Siletz sites.</td>
<td>Kenneth Wells</td>
<td>Heather Anderson</td>
<td>Motion unanimously carried.</td>
</tr>
</tbody>
</table>
Case 2016-0549  Motion to deny request.
Motion by: Kenneth Wells; Seconded by: Dianne Armstrong. Motion carried with Kate James recused.

Case 2016-0582  Motion to deny technician license and impose $1,000 civil penalty per violation.
Motion by: Cyndi Vipperman; Seconded by: Heather Anderson. Motion unanimously carried.

Case 2016-0259  Motion to deny request.
Motion by: Christine Chute; Seconded by: Kenneth Wells. Motion unanimously carried.

Case 2013-0304  Motion to grant request.
Motion by: Dianne Armstrong; Seconded by: Cyndi Vipperman. Motion unanimously carried.

Case 2015-0445  Motion to grant request.
Motion by: Rachael DeBarmore; Seconded by: Kenneth Wells. Motion unanimously carried.

Case 2016-0039  Motion to accept signed Consent Order.
Motion by: Dianne Armstrong; Seconded by: Cyndi Vipperman. Motion unanimously carried.

Case 2015-0521  Motion to reduce UA frequency to 18 per year.
Motion by: Kenneth Wells; Seconded by: Rachael DeBarmore. Motion unanimously carried.

Case 2016-0527  Motion to revoke pharmacist license and impose $1,000 civil penalty per violation.
Motion by: Kenneth Wells; Seconded by: Heather Anderson. Motion unanimously carried.

Case 2016-0501  Motion to revoke technician license and impose $1,000 civil penalty per violation.
Motion by: Dianne Armstrong; Seconded by: Cyndi Vipperman. Motion unanimously carried.

Case 2016-0485  Motion to deny technician license.
Motion by: Kenneth Wells; Seconded by: Heather Anderson. Motion unanimously carried.

Case 2016-0433  Motion to deny technician license and impose $1,000 civil penalty per violation.
Motion by: Dianne Armstrong; Seconded by: Cyndi Vipperman. Motion unanimously carried.

Case 2016-0581  Motion to deny technician license and impose $1,000 civil penalty per violation.
Motion by: Kenneth Wells; Seconded by: Dianne Armstrong. Motion unanimously carried.

Case 2016-0528  Motion to grant technician license with Board direction.
Motion by: Dianne Armstrong; Seconded by: Cyndi Vipperman. Motion unanimously carried.

Case 2016-0508  Motion to grant pharmacist license.
Motion by: Kenneth Wells; Seconded by: Dianne Armstrong. Motion unanimously carried.

Case 2016-0550  Motion to grant pharmacist license.
Motion by: Rachael DeBarmore; Seconded by: Heather Anderson. Motion unanimously carried.
Case 2016-0546  Motion to deny technician license and impose $1,000 civil penalty per violation.  
Motion by: Kenneth Wells; Seconded by: Dianne Armstrong.  Motion unanimously carried.

Case 2016-0477  Motion to deny technician license.  
Motion by: Dianne Armstrong; Seconded by: Cyndi Vipperman.  Motion unanimously carried.

Case 2016-0522  Motion to impose $10,000 civil penalty per violation against outlet, plus $4,500 stayed in Case No. 2015-0267.  
Motion by: Kenneth Wells; Seconded by: Christine Chute.  Motion unanimously carried.

Case 2016-0561  Motion to impose $1,000 civil penalty per violation against pharmacist and close case with Board direction.  
Motion by: Rachael DeBarmore; Seconded by: Kenneth Wells.  Motion unanimously carried.

Case 2016-0490  Motion to impose $1,000 civil penalty per violation against Pharmacist-in-Charge.  
Motion by: Kenneth Wells; Seconded by: Cyndi Vipperman.  Motion unanimously carried.

Motion to close with Board direction.  
Motion by: Heather Anderson; Seconded by: Kenneth Wells.  Motion unanimously carried.

Cases 2016-0548  Motion to impose $10,000 civil penalty per violation against outlet; and in case 2016-0513, close with Board direction.  
Motion by: Rachael DeBarmore; Seconded by: Cyndi Vipperman.  Motion unanimously carried.

Case: 2017-0006  Motion to deny pharmacist license and impose $1,000 civil penalty per violation.  
Motion by: Kenneth Wells; Seconded by: Heather Anderson.  Motion unanimously carried.

Motion to accept the items on the consent agenda  
Motion by: Christine Chute; Seconded by: Dianne Armstrong.  Motion unanimously carried.

Cases Closed with Board Direction:  